[Form 3] Bio-Rad Laboratories, Inc. Initial Statement of Beneficial Ownership

Rhea-AI Filing Summary

Rajat Mehta, listed as Executive Vice President, GBL Commercial Operations at Bio-Rad Laboratories (BIO), filed an initial Form 3 reporting the Section 16 beneficial-ownership status. The event date is 08/04/2025 and the form is signed 08/14/2025. The filing states no securities beneficially owned (0 shares) by the reporting person, with ownership shown as direct (D) where applicable.

Positive

• None.

Negative

• No securities beneficially owned by the reporting officer as of the event date, indicating zero reported equity stake
• Form 3 contains no equity grants or derivative holdings, so there are no disclosed incentives tied to company stock in this filing

Insights

Financial Analyst

TL;DR: An initial Section 16 filing shows the named officer currently holds no Bio-Rad shares; this is a routine disclosure with limited market impact.

The Form 3 documents the required initial disclosure for an officer and confirms no direct beneficial ownership of BIO stock as of the event date. For investors, the filing simply establishes the officer's starting ownership baseline; it neither indicates a purchase nor sale activity and contains no transaction values or option awards. This is informational and does not affect company financials.

Corporate Governance Expert

TL;DR: Filing meets Section 16 initial-report requirements and shows no reportable holdings by the officer; governance implications are minimal.

The submission satisfies disclosure obligations by identifying the reporting person, role (EVP, GBL Commercial Operations), issuer, and event date. The absence of beneficial ownership simplifies conflict-of-interest considerations but provides no insight into future grants or transactions. The document is a standard governance disclosure without material corporate-governance developments.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mehta Rajat

(Last) (First) (Middle)

C/O BIO-RAD LABORATORIES, INC.

1000 ALFRED NOBEL DR

(Street)

HERCULES CA 94547

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/04/2025

3. Issuer Name and Ticker or Trading Symbol
BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GBL Commercial Operations

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
No securities beneficially owned	0	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	/s/ Rajat Mehta	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rajat Mehta report on the Form 3 for BIO?

The Form 3 reports that Rajat Mehta, EVP, GBL Commercial Operations at BIO, holds no securities beneficially as of the event date 08/04/2025.

When was the Bio-Rad Form 3 event date and signature date?

The event date on the form is 08/04/2025 and the form is signed by the reporting person on 08/14/2025.

Does the Form 3 show any derivative or option holdings for BIO?

No. Table II for derivative securities shows no entries and the filing discloses no options, warrants, or convertible securities.

Is this Form 3 an amendment or the initial filing?

This is an initial Form 3 filing for the reporting person; the form indicates it was filed by one reporting person.

What is the reporting person’s role at Bio-Rad as listed on the Form 3?

The filing lists the reporting person as an Officer, specifically EVP, GBL Commercial Operations.